Sinphar Pharmaceutical Co Ltd (1734) - Total Assets
Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) holds total assets worth NT$6.42 Billion TWD (≈ $202.30 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sinphar Pharmaceutical Co Ltd - Total Assets Trend (2002–2025)
This chart illustrates how Sinphar Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Sinphar Pharmaceutical Co Ltd (1734) market capitalisation for the company's overall valuation and market capitalisation.
Sinphar Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Sinphar Pharmaceutical Co Ltd's total assets of NT$6.42 Billion consist of 41.1% current assets and 58.9% non-current assets. Review debt load of Sinphar Pharmaceutical Co Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 14.0% |
| Accounts Receivable | NT$713.86 Million | 11.6% |
| Inventory | NT$724.69 Million | 11.8% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$59.52 Million | 1.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Sinphar Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Sinphar Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinphar Pharmaceutical Co Ltd's current assets represent 41.1% of total assets in 2025, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, up from 6.1% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 5.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 11.8% of total assets.
Sinphar Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Sinphar Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
|
ChemPartner PharmaTech Co Ltd
SHE:300149
|
China | CN¥2.04 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
USA | $22.38 Million |
Sinphar Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.37 | 2.54 | 1.90 |
| Quick Ratio | 1.68 | 1.84 | 1.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.59 Billion | NT$1.61 Billion | NT$1.33 Billion |
Sinphar Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sinphar Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.74 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -2.3% |
| Total Assets | NT$6.15 Billion |
| Market Capitalization | $192.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sinphar Pharmaceutical Co Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Sinphar Pharmaceutical Co Ltd's assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sinphar Pharmaceutical Co Ltd (2002–2025)
The table below shows the annual total assets of Sinphar Pharmaceutical Co Ltd from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$6.15 Billion ≈ $193.85 Million |
-2.31% |
| 2024-12-31 | NT$6.30 Billion ≈ $198.43 Million |
+0.75% |
| 2023-12-31 | NT$6.25 Billion ≈ $196.94 Million |
+1.07% |
| 2022-12-31 | NT$6.19 Billion ≈ $194.87 Million |
-0.57% |
| 2021-12-31 | NT$6.22 Billion ≈ $195.99 Million |
+1.53% |
| 2020-12-31 | NT$6.13 Billion ≈ $193.03 Million |
+3.56% |
| 2019-12-31 | NT$5.92 Billion ≈ $186.40 Million |
+0.65% |
| 2018-12-31 | NT$5.88 Billion ≈ $185.19 Million |
-2.73% |
| 2017-12-31 | NT$6.04 Billion ≈ $190.39 Million |
-2.63% |
| 2016-12-31 | NT$6.21 Billion ≈ $195.54 Million |
-2.82% |
| 2015-12-31 | NT$6.39 Billion ≈ $201.21 Million |
-1.20% |
| 2014-12-31 | NT$6.46 Billion ≈ $203.65 Million |
+13.33% |
| 2013-12-31 | NT$5.70 Billion ≈ $179.69 Million |
+25.74% |
| 2012-12-31 | NT$4.54 Billion ≈ $142.90 Million |
-2.22% |
| 2011-12-31 | NT$4.64 Billion ≈ $146.14 Million |
+24.92% |
| 2010-12-31 | NT$3.71 Billion ≈ $116.99 Million |
+3.60% |
| 2009-12-31 | NT$3.58 Billion ≈ $112.93 Million |
-0.25% |
| 2008-12-31 | NT$3.59 Billion ≈ $113.20 Million |
+13.54% |
| 2007-12-31 | NT$3.16 Billion ≈ $99.70 Million |
+14.05% |
| 2006-12-31 | NT$2.77 Billion ≈ $87.42 Million |
-2.26% |
| 2005-12-31 | NT$2.84 Billion ≈ $89.45 Million |
+20.99% |
| 2004-12-31 | NT$2.35 Billion ≈ $73.93 Million |
+13.88% |
| 2003-12-31 | NT$2.06 Billion ≈ $64.92 Million |
+24.74% |
| 2002-12-31 | NT$1.65 Billion ≈ $52.05 Million |
-- |
About Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more